Impact of legislative changes on patterns of antipsychotic prescribing and self-poisoning in Scotland: 2000-06

Journal of Toxicological Sciences

Volumn 32, Issue 1, 2007, Pages 1-7

  Poon, H ^a   Elliot, V ^b   Bateman, D N ^a   Waring, W Stephen ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b NHS LOTHIAN   (United Kingdom)

Author keywords

Antipsychotic; Epidemiology; Poisoning; Thioridazine

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BENPERIDOL; CHLORPROMAZINE; CLOZAPINE; DROPERIDOL; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; LOXAPINE; OLANZAPINE; OXYPERTINE; PERICIAZINE; PERPHENAZINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SERTINDOLE; SULPIRIDE; THIORIDAZINE; ZOTEPINE; ZUCLOPENTHIXOL;

ARTICLE; CARDIOTOXICITY; DATA ANALYSIS; DRUG LEGISLATION; DRUG OVERDOSE; DRUG SAFETY; HOSPITAL ADMISSION; HUMAN; INCIDENCE; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; SELF POISONING; STATISTICAL ANALYSIS; UNITED KINGDOM;

ANTIPSYCHOTIC AGENTS; HOSPITALIZATION; HUMANS; LEGISLATION, DRUG; OVERDOSE; PHYSICIAN'S PRACTICE PATTERNS; SCHIZOPHRENIA; SCOTLAND; THIORIDAZINE;

EID: 33847406614     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.32.1     Document Type: Article

References (19)

1. Baca-Garcia, E., Diaz-Sastre, C., Saiz-Ruiz, J. and de Leon, J. (2002): How safe are psychiatric medications after a voluntary overdose? Eur. Psychiatry., 17, 466-470.
2. Bateman, D.N., Good, A.M., Afshari, R. and Kelly, C.A. (2003): Effects of licence change on prescribing and poisons enquiries for antipsychotic agents in England and Scotland. Br. J. Clin. Pharmacol., 55, 596-603.
3. Buckley, N.A., Whyte, I.M. and Dawson, A.H. (1995): Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. J. Toxicol. Clin. Toxicol., 33, 199-204.
4. Burns, T., Christova, L., Cooper, S., Harrison, G., McKendrick, J., Laugharne, R., Obuaya, T., McCreadie, R., O'Brien, S., Perrington, S.and Stephenson, D. (2006) Maintenance antipsychotic medication patterns in outpatient schizophrenia patients: A naturalistic cohort study. Acta Psychiatr. Scand., 113, 126-134.
5. Griffiths, C. and Flanagan, R.J. (2005): Fatal poisoning with antipsychotic drugs, England and Wales 1993-2002. J. Psychopharmacol., 19, 667-674.
6. Hanssens, L., De Hert, M., Wampers, M., Reginster, J.Y. and Peuskens, J. (2006): Pharmacological treatment of ambulatory schizophrenic patients in Belgium. Clin. Pract. Epidemol. Ment. Health, 2, 11.
7. Harding, C.M., Brooks, G.W., Ashikaga, T., Strauss, J.S. and Breier, A.(1987): The Vermont longitudinal study of persons with severe mental illness, II: Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. Am. J. Psychiatry, 144, 727-735.
8. Isbister, G.K., Murray, L., John, S., Hackett, L.P., Haider, T., O'Mullane, P., Gosselin, S. and Daly, F. (2006): Amisulpride deliberate self-poisoning causing severe cardiac toxicity including QT prolongation and torsades de pointes. Med. J. Aust., 184, 354-356.
9. Lin, C.H., Chen, M.C., Wang, S.Y. and Lin, C.Y. (2004): Predictive factors for QTc prolongation in schizophrenic patients taking antipsychotics. Formos Med. Assoc., 103, 437-441.
10. Medicines and Healthcare Products Regulatory Agency (MHRA) (2000): MHRA (Medicines) Restricts the Use of Thioridazine. MHRA Press Release 2000/0734. London.
11. Mitchell, M. (2000): StatsDirect. JAMA., 284, 1988.
12. National Institute for Clinical Excellence (2002): Technology Appraisal Guidance No. 43. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. London: National Institute for Clinical Excellence.
13. Rapoport, M., Mamdani, M., Shulman, K.I., Herrmann, N. and Rochon, P.A. (2005): Antipsychotic use in the elderly: Shifting trends and increasing costs. Int. J. Geriatr. Psychiatry, 20, 749-753.
14. Reilly, J.G., Ayis, S.A., Ferrier, I.N., Jones, S.J. and Thomas, S.H. (2000): QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet, 355, 1048-1052.
15. Silva de Lima, M., de Jesus Mari, J., Breier, A., Maria Costa, A., Ponde de Sena, E. and Hotopf, M. (2005): Quality of life in schizophrenia: A multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics. J. Clin. Psychiatry, 66, 831-838.
16. Stollberger, C., Huber, J.O. and Finsterer, J. (2005): Antipsychotic drugs and QT prolongation. Int. Clin. Psychopharmacol., 20, 243-251.
17. Trenton, A., Currier, G. and Zwemer, F. (2003): Fatalities associated with therapeutic use and overdose of atypical antipsychotics. CNS Drugs, 17, 307-324.
18. Wheeler, A. (2006): Atypical antipsychotic use for adult outpatients in New Zealand's Auckland and Northland regions. N. Z. Med. J., 119, 2055.
19. Witchel, H.J. and Hancox, J.C. (2000): Familial and acquired long QT syndrome and the cardiac rapid delayed rectifier potassium current. Clin. Exp. Pharmacol. Physiol., 27, 753-766.